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Abstract
Rheumatoid arthritis is a chronic inflammatory disease,
associated with an excess of cardiovascular morbidity and
mortality due to accelerated atherosclerosis. Oxidized low-
density lipoprotein (oxLDL), the antibodies against oxLDL and
the lipoprotein-associated phospholipase A2 (Lp-PLA2) may play
important roles in inflammation and atherosclerosis. We
investigated the plasma levels of oxLDL and Lp-PLA2 activity as
well as the autoantibody titers against mildly oxLDL in patients
with early rheumatoid arthritis (ERA). The long-term effects of
immunointervention on these parameters in patients with active
disease were also determined. Fifty-eight ERA patients who met
the American College of Rheumatology criteria were included in
the study. Patients were treated with methotrexate and
prednisone. Sixty-three apparently healthy volunteers also
participated in the study and served as controls. Three different
types of mildly oxLDL were prepared at the end of the lag,
propagation and decomposition phases of oxidation. The serum
autoantibody titers of the IgG type against all types of oxLDL
were determined by an ELISA method. The plasma levels of
oxLDL and the Lp-PLA2 activity were determined by an ELISA
method and by the trichloroacetic acid precipitation procedure,
respectively. At baseline, ERA patients exhibited elevated
autoantibody titers against all types of mildly oxLDL as well as
low activity of the total plasma Lp-PLA2  and the Lp-PLA2
associated with the high-density lipoprotein, compared with
controls. Multivariate regression analysis showed that the
elevated autoantibody titers towards oxLDL at the end of the
decomposition phase of oxidation and the low plasma Lp-PLA2
activity are independently associated with ERA. After
immunointervention autoantibody titers against all types of
oxLDL were decreased in parallel to the increase in high-density
lipoprotein-cholesterol and high-density lipoprotein-Lp-PLA2
activity. We conclude that elevated autoantibody titers against
oxLDL at the end of the decomposition phase of oxidation and
low plasma Lp-PLA2  activity are feature characteristics of
patients with ERA, suggesting an important role of these
parameters in the pathophysiology of ERA as well as in the
accelerated atherosclerosis observed in these patients.
Introduction
Rheumatoid arthritis is a chronic inflammatory condition of
unknown etiology affecting primarily the synovium, leading to
joint damage and bone destruction [1]. Rheumatoid arthritis
causes significant morbidity as a result of synovial inflamma-
tion, joint destruction and associated disability. Several inves-
tigators have reported an excess of cardiovascular morbidity
and mortality among rheumatoid arthritis patients. In active
Apo A-I = apolipoprotein A-I; Apo B = apolipoprotein B-100; CRP = C-reactive protein; DMARDs = disease-modifying antirheumatic drugs; ELISA 
= enzyme-linked immunosorbent assay; ERA = early rheumatoid arthritis; HDL = high-density lipoprotein; Lp(a) = lipoprotein (a); Lp-PLA2 = lipopro-
tein-associated phospholipase A2; HDL-Lp-PLA2 = high-density lipoprotein-associated phospholipase A2; IL = interleukin; LDL = low-density lipopro-
tein; oxLDL = oxidized low-density lipoprotein; oxLDLD = oxidized low-density lipoprotein in the decomposition phase; oxLDLL = oxidized low-density 
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rheumatoid arthritis, the majority of cardiovascular deaths
result from accelerated atherosclerosis [2-5].
Oxidative modification of low-density lipoprotein (LDL) is an
important event in the development and progression of athero-
sclerosis. Oxidized low-density lipoprotein (oxLDL) is present
in atherosclerotic lesions of humans and animal models, and
promotes atherosclerosis by several mechanisms [6-9]. oxLDL
has been detected in patients with systemic lupus erythema-
tosus and the antiphospholipid syndrome and also in the syn-
ovium and synovial fluids of rheumatoid arthritis patients
[10,11].
During LDL oxidation both the lipids and apolipoprotein B-100
(Apo B) undergo a variety of chemical changes via radical-
mediated reactions as well as modifications by chemically
active products formed on oxLDL particles [12]. An important
biochemical change that takes place during LDL oxidation is
the hydrolysis of its content in oxidized phospholipids and the
production of lysophosphatidylcholine. This reaction is cata-
lyzed by the lipoprotein-associated phospholipase A2 (Lp-
PLA2), also known as platelet-activating factor acetylhydrolase
[13]. Lp-PLA2 exhibits a Ca2+-independent phospholipase A2
activity and preferentially hydrolyses biologically active phos-
pholipids containing short acyl groups at the sn-2 position,
such as platelet-activating factor and oxidized phospholipids
[13]; this enzyme therefore plays important roles in inflamma-
tory reactions and atherosclerosis [14]. In human plasma Lp-
PLA2 is associated mainly with LDL, whereas a small propor-
tion of circulating enzyme activity is also associated with high-
density lipoprotein (HDL) [13,15]. Data from large Caucasian
population studies have demonstrated an independent associ-
ation between plasma Lp-PLA2 (which represents mainly the
LDL-associated Lp-PLA2) and the risk of future cardiovascular
events [16,17]. In contrast to the total plasma enzyme, several
lines of evidence suggest that HDL-associated Lp-PLA2 activ-
ity (HDL-Lp-PLA2), although at low levels in plasma, may con-
tribute to the antiatherogenic effects of this lipoprotein [13].
oxLDL is immunogenic and some of its constituents (oxidized
phospholipids, aldehydes and lysophosphatidylcholine) play
important roles in the oxLDL antigenicity, participating in the
formation of several different epitopes. These epitopes are
recognized by specific autoantibodies, which are present in
serum of healthy individuals as well as in various pathologic
conditions [18]. We recently showed, using various types of
mildly oxLDL as antigens, that the extent of LDL oxidation and
the levels of LDL-associated Lp-PLA2 activity significantly influ-
ence the antibody titers against oxLDL in patients with stable
angina [19,20]. Furthermore, we recently showed that the
LDL-associated Lp-PLA2 plays an important role in modulating
the immune responses against various types of mildly oxLDL
observed after an acute coronary syndrome without persistent
elevation of the ST segment [21].
The aim of the present study was to investigate the plasma lev-
els of oxLDL and Lp-PLA2 activity as well as the autoantibody
titers against various types of mildly oxidized LDL in patients
with early rheumatoid arthritis (ERA). The long-term effects of
immunointervention on these parameters in patients with
active disease were also determined.
Materials and methods
Patients
Fifty-eight consecutive patients with ERA (14 men and 44
women) who met the American College of Rheumatology
1987 criteria for rheumatoid arthritis [22] and 63 apparently
healthy nonsmoking volunteers (controls) were investigated.
ERA patients were >18 years of age and had early inflamma-
tory disease (disease duration <12 months) without prior use
of disease-modifying antirheumatic drugs (DMARDs) and/or
corticosteroids. All patients were recruited from the outpatient
rheumatology clinic of the University Hospital of Ioannina,
Greece. Details on the eligibility criteria for inclusion or exclu-
sion from the study were reported in our previously published
prospective, controlled study [23].
ERA patients were treated with methotrexate (0.2 mg/kg/
week), and prednisone (7.5 mg/day). The dose of methotrex-
ate remained stable during the study, while the dose of pred-
nisone was tapered to 5 mg/day according to the patients'
clinical response. Disease activity was assessed by measuring
the disease activity score for 28 joint indices [24], while the
clinical response was evaluated according to the American
College of Rheumatology 50% response criteria [25]. All
patients were followed up every month for the first 3 months,
and every 3 months thereafter. During the follow-up period, a
questionnaire concerning changes in dietary habits was care-
fully completed by all patients. The body weight was also
measured appropriately in each visit. Overnight fasting blood
samples were obtained at baseline and after 12 months fol-
low-up from both the ERA patients and the control group. The
Ethics Committee of the University Hospital of Ioannina
approved the study and written informed consent was
obtained from each patient and each healthy volunteer.
Measurement of autoantibody titers against oxidized 
low-density lipoprotein
LDL (density = 1.019–1.063 g/ml) was isolated by sequential
ultracentrifugation from pooled fresh plasma [26]. LDL, at a
final concentration of 100 μg protein/ml, was oxidized in the
presence of 5 μM CuSO4 for up to 3 hours at 37°C under con-
tinuous monitoring of the increase in the absorbance at 234
nm, as we recently described [19,20]. Oxidation of LDL was
terminated by the addition of 0.01% ethylenediamine tetraace-
tic acid either at the end of the lag phase (oxLDLL), at the end
of the propagation phase (oxLDLP), or during the decomposi-
tion phase (oxLDLD), 3 hours after the onset of oxidation
[19,20]. The serum autoantibody titers of the IgG type against
all types of oxLDL were determined by an ELISA method, asAvailable online http://arthritis-research.com/content/9/1/R19
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we recently described [19,20]. The results were expressed as
the ratio of antibody binding to various types of oxLDL versus
LDL [19,20].
Determination of lipoprotein-associated phospholipase 
A2 activity
The Lp-PLA2 activity in plasma and in HDL-rich plasma, after
the sedimentation of all Apo B-containing lipoproteins with
dextran sulfate–magnesium chloride (HDL-Lp-PLA2), was
measured by the trichloroacetic acid precipitation procedure,
using 1-O-hexadecyl-2- [3H-acetyl]-sn-glycero-3-phospho-
choline as a substrate at a final concentration of 100 μmol/l.
The reaction was performed for 10 min at 37°C and the Lp-
PLA2 activity was expressed as nanomoles of 1-O-hexadecyl-
2-acetyl-sn-glycero-3-phosphocholine degraded per minute
per milliliter of plasma [20,27,28]. The minimum detection limit
of the assay is 0.8 nmol/min/ml plasma, whereas the intra-
assay and inter-assay coefficients of variation are 3.3–4.2%
and 7.1–8.0%, respectively.
Analytical methods
Serum lipids were determined after 12 hours overnight fast.
Total cholesterol, triglycerides and HDL-cholesterol levels
were determined on the Olympus AU560 Clinical Chemistry
analyzer (Hamburg, Germany) as previously described [28].
LDL-cholesterol was estimated by calculation, using the
Friedewald formula [29]. Serum Apo B and apolipoprotein A-I
(Apo A-I) levels were measured by immunonephelometry with
the aid of a Behring Nephelometer BN100 and reagents (anti-
bodies and calibrators) from Behring Diagnostics GmbH (Lie-
derbach, Germany). Serum lipoprotein (a) (Lp(a)) levels were
determined by an enzyme immunoassay method (Macra Lp(a);
Terumo Medical Corporation Diagnostic Division, Elkton, MD,
USA) [27]. C-reactive protein (CRP) and IgM rheumatoid fac-
tor were measured by nephelometry. The erythrocyte sedimen-
tation rate was measured by the modified Westergren method.
Statistical analysis
Data were expressed as the mean ± standard deviation. Sta-
tistical analysis was performed using the paired Student's t
test for comparisons between baseline and post-treatment val-
ues, while one-way analysis of variance followed by the least
significant difference post hoc test was used for comparisons
between individual groups. Comparison between baseline and
post-treatment CRP levels was performed using the Kruskal–
Wallis test while CRP levels between individual groups were
compared using the Mann–Whitney U test. Correlation
between variables was examined using the Pearson's correla-
tion coefficient. We used multivariate logistic regression anal-
ysis to calculate the adjusted odd ratios and 95% confidence
intervals for the two study groups.
Matched groups were constructed taking into account the sig-
nificant factors as derived from the univariate logistic regres-
sion analysis. The model selection used the backward
stepwise method (likelihood ratios), and variables at a P value
less than 0.05 were retained in the model as independent var-
iables. The variables included in the univariate analysis were
the following: age, total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides, Apo B, Apo A-I, autoantibody titers
against oxLDLL, oxLDLP and oxLDLD, plasma Lp-PLA2 activity,
HDL-Lp-PLA2 activity (continuous variables) and female gen-
der (dichotomous variable). All statistical analyses were car-
ried out with SPSS 12.0 (SPSS Inc., Chicago, IL, USA). In all
cases, P < 0.05 was considered statistically significant.
Results
Patients' characteristics and lipid profile
Fifty-eight patients with ERA and 63 apparently healthy volun-
teers participated in the study. The clinical and biochemical
characteristics of the study population are presented in Table
1. There was no observed difference in sex distribution, age
and body mass index between ERA patients and controls. As
expected, ERA patients exhibited increased levels of the
inflammatory markers CRP and erythrocyte sedimentation rate
and had a high disease activity score as measured by the dis-
ease activity score for 28 joint indices (Table 1). In addition,
ERA patients exhibited a mild dyslipidemia characterized by an
increase in the serum levels of total cholesterol, LDL-choles-
terol, triglycerides and Apo B as well as by a decrease in the
serum levels of HDL-cholesterol and Apo A-I compared with
controls. No difference in the serum Lp(a) levels was observed
between the two study groups.
One year of therapy with DMARDs in ERA patients resulted in
a significant decrease of the inflammatory markers CRP and
the erythrocyte sedimentation rate as well as in the reduction
of the disease activity score for 28 joint indices (Table 1). In
addition, one year of therapy with DMARDs resulted in a sig-
nificant increase in the serum levels of total cholesterol, HDL-
cholesterol and Apo A-I compared with the respective base-
line values (Table 1). It should be noted that no female patient
was receiving hormone replacement therapy either at baseline
or during the follow-up period.
Lipoprotein-associated phospholipase A2 activity
At baseline, ERA patients exhibited a significantly lower activ-
ity of total plasma Lp-PLA2 and of HDL-Lp-PLA2, compared
with controls (Table 1). One year of therapy with DMARDs did
not influence the total plasma Lp-PLA2 but it significantly
increased the HDL-Lp-PLA2 activity (Table 1).
Autoantibody titers against oxidized low-density 
lipoprotein
Three types of mildly oxLDL were prepared and used as anti-
gens: oxLDLL at the end of the lag phase, oxLDLP at the end of
the propagation phase and oxLDLD at the decomposition
phase, 3 hours after the onset of oxidation. As shown in Table
2, ERA patients exhibited higher autoantibody titers against all
types of oxLDL at baseline compared with controls. Impor-Arthritis Research & Therapy    Vol 9 No 1    Lourida et al.
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tantly, the autoantibody titers against oxLDLP and oxLDLD were
inversely correlated with serum HDL-cholesterol levels (Figure
1). In addition, autoantibody titers against oxLDLD  were
inversely correlated with HDL-Lp-PLA2 activity (Figure 1). One
year of therapy with DMARDs resulted in a significant
decrease in autoantibody titers against all types of oxLDL in
ERA patients compared with the respective baseline values
(Table 2).
Association of autoantibody titers against oxidized LDL 
and plasma lipoprotein-associated phospholipase A2 
with early rheumatoid arthritis
We initially performed univariate analysis using the lipid param-
eters that were significant different between ERA patients and
controls, the antibody titers against the various types of oxLDL
and the Lp-PLA2 activity, in order to evaluate their relationships
with the presence of ERA. The results of this analysis showed
that only autoantibody titers against all types of oxLDL as well
as the low plasma Lp-PLA2 activity are associated with ERA
(Table 3). To further identify whether these parameters could
independently be associated with ERA, multivariate logistic
regression analysis was performed, taking into account all sta-
tistically significant factors as they derived from univariate anal-
ysis. In the multivariate analysis model we therefore included
the autoantibody titers against oxLDLL, oxLDLP and oxLDLD,
and the plasma Lp-PLA2 activity as defined from univariate
analysis. In this analysis ERA showed significant associations
only with autoantibody titers against oxLDLD and plasma Lp-
PLA2 activity (Table 4).
Discussion
The present study shows for the first time that ERA patients
exhibit low plasma Lp-PLA2 activity and elevated autoantibody
titers against mildly oxidized types of LDL (oxLDLL, oxLDLP and
oxLDLD), compared with controls. The low Lp-PLA2 activity is
in accordance with previously published data by our group,
indicating that patients with active juvenile rheumatoid arthritis
presented with lower plasma Lp-PLA2 activity compared with
those with inactive disease or to controls [30]. The present
study further shows that the low Lp-PLA2 activity is independ-
ently associated with ERA. It is well established that the main
cellular source of the plasma form of Lp-PLA2 is monocytes,
which secrete this enzyme during their differentiation into mac-
rophages [31]. The cellular expression of plasma Lp-PLA2 is
regulated by various factors, including the differentiation state
of the cell and the degree of activation by proinflammatory
mediators [13,32]. Most of the proinflammatory mediators
(lipopolysaccharide, tumor necrosis factor alpha, IL-1, IL-8,
and interferon gamma) inhibit Lp-PLA2 expression by macro-
phages in vitro [13]. The reduction in plasma Lp-PLA2 activity
found in ERA patients could therefore be attributed to the
inflammation-induced decrease in the enzyme expression.
According to our previously published results, however,
another important determinant of the plasma Lp-PLA2 activity
Table 1
Clinical characteristics and lipid profile of early rheumatoid arthritis patients and controls
Controls (n = 63) Early rheumatoid arthritis patients
Baseline (n = 58) Post-treatment (n = 56)
Sex (males/females) 20/43 14/44 13/43
Age (years) 58.4 ± 17.7 53.6 ± 15.3 54.7 ± 14.8
Body mass index (kg/m2) 25.8 ± 6.5 25.5 ± 3.3 25.8 ± 3.1
IgM rheumatoid factor (+/-) 0/0 45/13 44/13
C-reactive protein (mg/dl) 3 (1–5) 22 (7–104) 3 (1–5)‡
Disease activity score for 28 joint indices - 5.8 ± 0.9 2.7 ± 1.0‡
Erythrocyte sedimentation rate (mm/h) 5.2 ± 3.1 48.0 ± 19.7 14.6 ± 8.7‡
Total cholesterol (mg/dl) 190.4 ± 33.9 216.5 ± 50.3* 228.1 ± 42.1**
Low-density lipoprotein-cholesterol (mg/dl) 126.5 ± 31.3 141.6 ± 42.3* 140.4 ± 32.4
High-density lipoprotein-cholesterol (mg/dl) 51.1 ± 7.4 47.5 ± 11.8† 60.7 ± 13.4‡
Triglycerides (mg/dl) 97.1 ± 28.3 133.0 ± 58.2* 131.5 ± 56.1
Apolipoprotein B-100 (mg/dl) 93 ± 19 103 ± 28* 105 ± 30
Apolipoprotein A-I (mg/dl) 144 ± 23 127 ± 27† 152 ± 22‡
Lipoprotein (a) (mg/dl) 10.6 (0.8–28.0) 11.2 (2.5–39.7) 8.6 (2.5–38.1)
Plasma lipoprotein phospholipase A2 activity (nmol/ml/min) 58.6 ± 14.0 47.1 ± 19.3† 45.7 ± 14.6
High-density lipoprotein-associated lipoprotein phospholipase A2 activity (nmol/ml/min) 3.4 ± 1.3 2.7 ± 1.0* 3.6 ± 1.3‡
Data presented as the mean ± standard deviation or as the median (range). *P < 0.001 and †P < 0.0001 compared with controls, ‡P < 0.001 and 
**P < 0.01 compared with baseline values.Available online http://arthritis-research.com/content/9/1/R19
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is the plasma LDL level [27,28]. Indeed, Lp-PLA2 in plasma is
mainly bound on LDL particles, whereas a small proportion is
associated with HDL [13]. We may consequently suggest that
the low levels of enzyme activity in the plasma of ERA patients
at baseline could be the combined effect of the inflammation-
induced reduction of enzyme secretion from macrophages
and the expected increase in plasma enzyme levels due to the
elevation of LDL-cholesterol in plasma of ERA patients.
The dependence of the plasma Lp-PLA2 levels from the LDL-
cholesterol levels could also explain our results showing that
therapy with DMARDs did not affect either the plasma LDL-
cholesterol levels or the plasma Lp-PLA2 activity. A factor that
could also influence the plasma Lp-PLA2 levels in ERA patients
is Lp(a). Indeed, we [33] and others [34] have previously
shown that Lp(a) contains several-fold greater Lp-PLA2 activity
Table 2
Autoantibody titers against various types of oxidatively modified low-density lipoprotein (oxLDL) in early rheumatoid arthritis 
patients and controls
Antigen Controls (n = 63) Early rheumatoid arthritis patients
Baseline (n = 58) Post-treatment (n = 56)
oxLDL in the lag phase 0.919 ± 0.271 1.131 ± 0.229* 0.872 ± 0.198†
oxLDL in the propagation phase 0.962 ± 0.289 1.223 ± 0.278* 1.045 ± 0.300‡
oxLDL in the decomposition phase 0.985 ± 0.376 1.375 ± 0.327* 1.144 ± 0.247**
Data presented as the mean ± standard deviation. *P < 0.0001 compared with controls, †P < 0.001, ‡P < 0.01 and **P < 0.05 compared with 
baseline values.
Figure 1
Correlation between serum levels of high-density lipoprotein-cholesterol and autoantibody titers against oxidized low-density lipoprotein Correlation between serum levels of high-density lipoprotein-cholesterol and autoantibody titers against oxidized low-density lipoprotein. Correlation 
between serum levels of high-density lipoprotein (HDL)-cholesterol and autoantibody titers against (a) oxidized low-density lipoprotein in the propa-
gation phase (oxLDLP) and (b) oxidized low-density lipoprotein in the decomposition phase (oxLDLD) in early rheumatoid arthritis patients at baseline. 
(c) Correlation between HDL-associated lipoprotein-associated phospholipase A2 (HDL-Lp-PLA2) activity and autoantibody titers against oxLDLD in 
early rheumatoid arthritis patients at baseline.Arthritis Research & Therapy    Vol 9 No 1    Lourida et al.
Page 6 of 8
(page number not for citation purposes)
compared with LDL when assayed at equimolar protein con-
centrations. Importantly, recent results have provided evi-
dence that the Lp(a)-associated Lp-PLA2  may play an
important role by degrading oxidized phospholipids that are
preferentially sequestered on Lp(a) [35]. It is unlikely, however,
that the Lp(a)-associated Lp-PLA2 activity might have influ-
enced the plasma levels of this enzyme in ERA patients since
the mean serum levels of Lp(a) in our patients as well as in con-
trols are between 8.6 and 11.2 mg/dl – according to our pre-
viously published results, the plasma levels as well as the
distribution of Lp-PLA2 between LDL and HDL can be influ-
enced by the presence of Lp(a) only when plasma levels of this
lipoprotein exceed 30 mg/dl [33].
An important observation of the present study is that ERA
patients exhibited higher autoantibody titers against all types
of mildly oxLDL (oxLDLL, oxLDLP and oxLDLD) at baseline com-
pared with controls. One year of therapy with DMARDs
resulted in a significant decrease of autoantibody titers against
all types of oxLDL compared with the respective baseline val-
ues, a finding that could be attributed, at least partially, to the
repression of the immune system activation due to immu-
nointervention. Importantly, the antibody titers against oxLDLD
are independently associated with ERA, thus providing evi-
dence that such types of mildly oxLDL may be implicated in the
pathophysiology of ERA. Indeed, previously published results
showed that modified LDL with characteristics of minimally
modified LDL, but not extensively oxidized LDL, is present in
the synovial fluid of patients with rheumatoid arthritis [36].
Another important finding of the present study is that ERA
patients exhibit low plasma HDL-cholesterol levels at baseline.
According to our previously published results, this phenome-
non could be at least partially attributed to the increased activ-
ity of the cholesterol ester transferring protein observed in
plasma of ERA patients [23]. The present study further shows
Table 3
Univariate logistic regression analysis of factors associated with the presence of early rheumatoid arthritis
Odds ratio 95% confidence interval P value
Age 1.009 0.982–1.036 Not significant
Female gender 1.014 0.965–1.123 Not significant
Total-cholesterol 0.998 0.990–1.006 Not significant
Low-density lipoprotein-cholesterol 0.960 0.991–1.010 Not significant
High-density lipoprotein-cholesterol 0.969 0.931–1.008 Not significant
Triglycerides 0.998 0.991–1.006 Not significant
Apolipoprotein B-100 1.012 0.934–1.134 Not significant
Apolipoprotein A-I 0.985 0.876–1.078 Not significant
Antibodies against oxidized low-density lipoprotein in the lag phase 0.027 0.004–0.177 0.000
Antibodies against oxidized low-density lipoprotein in the propagation phase 0.029 0.005–0.171 0.000
Antibodies against oxidized low-density lipoprotein in the decomposition phase 0.034 0.008–0.152 0.000
Plasma lipoprotein phospholipase A2 activity 1.038 1.012–1.066 0.004
High-density lipoprotein-associated lipoprotein phospholipase A2 activity 1.021 0.897–1.245 Not significant
Table 4
Multivariate logistic regression analysis of factors associated with the presence of early rheumatoid arthritis
Odds ratio 95% confidence interval (β) P value
Antibodies against oxidized low-density lipoprotein in the lag phase 0.431 0.023–7.945 Not significant
Antibodies against oxidized low-density lipoprotein in the propagation phase 0.155 0.010–2.295 Not significant
Antibodies against oxidized low-density lipoprotein in the decomposition phase 0.047 0.008–0.282 0.001
Plasma lipoprotein phospholipase A2 activity 1.044 1.013–1.077 0.006
The model includes antibodies against oxidized low-density lipoprotein in the lag phase, the propagation phase and the decomposition phase, and 
plasma lipoprotein phospholipase A2 activity as defined from univariate analysis after adjustment for age and female gender.Available online http://arthritis-research.com/content/9/1/R19
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that HDL-cholesterol levels are inversely correlated with
autoantibody titers against oxLDLP and oxLDLD. Furthermore,
autoantibody titers against oxLDLD at baseline are inversely
correlated with HDL-Lp-PLA2. Several studies over the past
years have demonstrated that HDL exerts potent anti-inflam-
matory, antioxidant and antiatherogenic effects through its
constituents. Among these constituents, the enzyme Lp-PLA2
may have a prominent role by degrading proinflammatory oxi-
dized phospholipids formed on LDL during oxidation, thus lim-
iting their accumulation on oxLDL [13]. The negative
correlation between HDL-Lp-PLA2  activity and antibodies
against oxLDLD found in the present study could therefore be
attributed to the fact that oxLDLD compared with the other
types of oxLDL is enriched in oxidized phospholipids that sig-
nificantly contribute to the antigenicity of this type of oxLDL
[37]. These phospholipids are substrates for HDL-Lp-PLA2;
consequently the HDL-Lp-PLA2  activity could significantly
lower the levels of oxidized phospholipids formed on oxLDLD,
thus diminishing the antigenicity of this type of oxLDL. In addi-
tion to the HDL-Lp-PLA2, the Apo A-I content of HDL can bind
oxidized lipids and remove them from LDL, therefore signifi-
cantly contributing to the HDL-mediated retardation of LDL
oxidation and thus the prevention of oxLDL proinflammatory
activities [38].
According to our results, the low baseline levels of HDL-cho-
lesterol and HDL-Lp-PLA2 activity in ERA patients are signifi-
cantly increased after immunointervention, a phenomenon that
could be at least partially attributed to the immunointervention-
induced reduction in cholesterol ester transferring protein
activity [23]. The elevation of HDL-cholesterol and HDL-Lp-
PLA2 activity in ERA patients after immunointervention is asso-
ciated with a reduction in the autoantibody titers against
oxLDL. We may consequently suggest that the immunointer-
vention-induced reduction in the autoantibody titers against
oxLDL could be attributed not only to the repression of the
immune system activation, but also to the increase in plasma
HDL-cholesterol and HDL-Lp-PLA2 levels. Furthermore, this
action of DMARDs may represent a potentially antiatherogenic
effect of these drugs.
Conclusion
The present study shows for the first time that ERA patients
exhibit low plasma Lp-PLA2 and HDL- Lp-PLA2 activities and
elevated autoantibody titers against mildly oxLDL. The low
plasma Lp-PLA2  activity and the increased titers against
oxLDLD are independently associated with ERA, suggesting
an important role of these parameters in the pathophysiology
of ERA. This hypothesis needs to be further supported by
large-scale clinical studies.
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